---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-032770"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:27:26.196022+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences: nano-PFA reduces benign thyroid nodule volume >50% in feasibility study

## Summary
- First-in-human study (30 patients) shows ≥50% nodule volume reduction and symptomatic relief within 1 month.
- Results presented at 2024 American Thyroid Association Annual Meeting by PI Dr. Stefano Spiezia.
- No residual fibrosis or scarring observed; potential advantage over thermal ablation and surgery.
- Company plans to commence pivotal trial mid-2025 to support U.S. labeling indication.
- Study NCT06117085 fully enrolled; long-term follow-up ongoing.

## SEC filing metadata
- accession: 0001437749-24-032770
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774924032770/0001437749-24-032770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774924032770/plse20241031c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-032770
- JSON: https://secwatch.observer/filing/0001437749-24-032770.json
- Plain text: https://secwatch.observer/filing/0001437749-24-032770.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.